A new study reveals that glucagon-like peptide-1 receptor agonists (GLP-1), which include weight loss and diabetes meds Ozempic, Wegovy, Mounjaro or Zepbound, may help users overcome alcoholism and opioid addiction.

A new study suggests that medications like Ozempic could help reduce the risk of overdose and alcohol intoxication in people with substance use disorders.

THURSDAY, Oct. 17, 2024 (HealthDay News) -- Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds.

New research shows that Ozempic and similar drugs reduce opioid overdoses by 40% and alcohol intoxication by 50% in people with substance use disorders. These medications, often prescribed for diabetes and weight issues,

GLP-1 receptor agonists and similar drugs may protect people with opioid or alcohol use disorder from opioid overdose and alcohol intoxication, a large real-world study suggested.

Ozempic, a popular drug for treating diabetes and promoting weight loss, has emerged as an unexpected weapon in the fight against opioid and alcohol addiction.

Weight-loss drugs like Ozempic and Mounjaro, which also treat diabetes, may help users battling drug and alcohol abuse as well. A study published in the Addiction medical journal Wednesday showed roughy 1.

Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds.